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The metastasis associated protein S100A4: role in tumour
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The metastasis associated protein S100A4 is a small calcium binding protein that is associated with metastatic tumors and appears to
be a molecular marker for clinical prognosis. Below we discuss its biochemical properties and possible cellular functions in metastasis
including cell motility, invasion, apoptosis, angiogenesis and differentiation.
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S100A4 AND CANCER PROGNOSIS
S100A4 (also known as mts1 pEL-98, 18A2, p9Ka, CAPL, calvasculin,
Fspl) is a member of the S100 family of calcium binding proteins
and has been categorized as a metastasis-associated protein. S100A4
is a candidate as a molecular marker for metastatic potential with
high prognostic significance. Support for S100A4 as a prognostic
marker was first obtained from two studies of patients with early
stages of breast cancer. Rudland et al (2000) reported a significant
difference in the 19-year survival rate for patients with invasive but
operable stage I and stage II breast cancer depending on the S100A4
status of their tumours (80% for S100A4-negative vs 11% for
S100A4-positive, Po0.0001). The median survival of the S100A4-
negative group was 4228 months compared to 47 months for the
S100A4-positive group. Subsequent studies confirmed S100A4 as a
potential predictor for metastasis and mortality in early-stage breast
cancer. Patients with S100A4-positive early tumours had a
significantly worse 10-year survival than those with S100A4-negative
tumors (29.0 vs 68.9%, P¼ 0.001) (Lee et al, 2004). In fact, S100A4
was shown to be a significant marker of prognosis even for T1N0M0
breast cancers. This suggests that critical changes in metastatic
potential may be determined early in breast cancer disease using
markers such as S100A4.
In contrast to these data, Pedersen et al (2002) did not find a
significant correlation between S100A4 expression and clinical
outcome. Studies on 62 breast carcinomas of I–IV stages revealed
significant correlation of S100A4 immunoreactivily with histo-
logical grade and loss of oestrogen receptor but not with the
development of distant metastasis and patient survival. While
these results are different from those obtained by others (Ruland
et al and Lee et al), the discrepancy may be explained by fewer case
numbers, inclusion of all stages of disease, a relatively short period
of follow-up, and differences in sample storage conditions or
fixation methods. Nevertheless, the putative role of S100A4 protein
as a prognostic factor remains uncertain at this time. To further
clarify the prognostic significance of this protein, additional
studies of large number of cancer specimens and lengthy follow-up
are needed.
In addition to these data for breast cancer, an increase in S100A4
protein expression has been correlated with a worse prognosis for
patients with colorectal, gallbladder, bladder, esophageal, non-
small-cell lung, gastric, medulloblastoma, pancreatic and hepato-
cellular cancers (Rudland et al, 2000; Mazzucchelli, 2002; Cho et al,
2003; Heman et al, 2003; Cui et al, 2004; Missiaglia et al, 2004).
Since tumour size and histological grade do not sufficiently predict
metastatic potential, there is a need to identify markers to devise
treatment algorithms that guide physicians regarding which
patients should receive adjuvant chemotherapy treatment. Markers
such as S100A4 may help limit the use of chemotherapy with all its
known toxic side effects to those patients who will most benefit.
S100A4 EXPRESSION IS STRONGLY CORRELATED
WITH AN AGGRESSIVELY METASTATIC PHENOTYPE
Ebralidze et al (1989) first introduced the association of S100A4
(mts 1) with metastatic capacity of tumour cells in their report that
S100A4 mRNA expression level matched the metastatic potential of
several tumour cell lines. This was followed by reports that
transfection of either human or rat S100A4 DNA can induce a
metastatic phenotype upon nonmetastatic rat mammary tumour
cells (Davies et al, 1993; Grigorian et al, 1993), whereas inhibition
of S100A4 expression in metastatic cells can revert cells to a less
metastatic phenotype (Maelandsmo et al, 1996). Notably, S100A4
is not tumorigenic per se as evidenced by the failure of transgenic
mice overexpressing S100A4 to develop tumours (Ambartsumian
et al, 1996; Davies et al, 1996), but instead acts as a potential
inducer of metastasis in a given tumorigenic background.
Received 14 January 2005; revised 6 April 2005; accepted 6 April 2005;
published online 17 May 2005
*Correspondence: DM Helfman, E-mail: dhelfman@med.miami.edu
British Journal of Cancer (2005) 92, 1955 – 1958
& 2005 Cancer Research UK All rights reserved 0007 – 0920/05 $30.00
www.bjcancer.com
Transgenic mice generated with the S100A4 gene placed under the
regulation of the mouse mammary tumour virus promoter leading
to overexpression of S100A4 in lactating mammary glands yields
transgenic animals that are phenotypically normal. However,
crossing these transgenic mice with the GRS/A strain of mice (a
strain characterised by a high incidence of mammary tumours that
rarely metastasize) yielded a significant increase in mice that
developed mammary tumours which metastasized (Ambartsumian
et al, 1996). A similar result was obtained in mice bearing tumours
expressing the HER2/Neu oncogene. It was found that the progeny
from mice overexpressing S100A4 crossed with mice overexpres-
sing the HER2/Neu oncogene develop tumours that metastasize
more frequently and more rapidly than tumours in the parental
neu mice (Davies et al, 1996). Interestingly, S100A4 knockout
animals are able to develop spontaneous tumours at a late age
and demonstrate reduction of apoptosis possibly as a result
of a functional destabilisation of the tumour suppressor p53
(El-Naaman et al, 2004), a target protein of S100A4 (see below).
PROPOSED FUNCTIONS FOR S100A4
Studies to determine the mechanistic basis for S100A4 function have
shown a potential role for S100A4 in several different facets of
tumour progression including motility, invasion, and apoptosis
(Kriajevska et al, 1994; Takenaga et al, 1994a). Since S100A4 has no
known enzymatic activity, interactions with other proteins, both
intracellularly and extracellularly, are undoubtedly functionally
critical. The interaction between S100A4 and its known protein
partners has been shown to depend on both binding calcium
through two EF-hand motif and dimerization. It has been proposed
that S100A4 affects motility through its interaction with a nonmuscle
myosin, a proposal strengthened by the colocalisation of S100A4
with myosin at the leading edge of motile cells (Kim and Helfman,
2003). Deletion analysis localised the interaction of S100A4 to the
nonhelical C-term end of myosin heavy chain, specifically residues
1909–1937 of myosin heavy chain type Il-A, a region of MHC-IIA
that includes a PKC phosphorylated residue, Ser 1917 (Kriajevska
et al, 1998). Including S100A4 in an in vitro PKC kinase assay
decreases the phosphorylation of MHC-IIA proportional to increa-
sing amounts of S100A4 (Kriajevska et al, 1998). Despite the lack of a
known functional role for the phosphorylation of myosin at Ser 1917,
S100A4 decreases sedimentation suggesting that S100A4 may inhibit
myosin filament assembly. Murakami et al (2000) reproduced these
data using a 46 kDa C-term fragment of MHC-IIA, while also
demonstrating a similar effect on MHC-IIB upon phosphorylation by
PKC. Since PKC phosphorylation of MHC-IIA has no such effect on
filament assembly, they proposed that S100A4 and PKC phosphor-
ylation play parallel roles in the inhibition of polymerization of
MHC-IIA and IIB, respectively. Interestingly, another one of the
reported S100A4 protein partners, liprin b1 is prevented from being
phosphorylated by the same two protein kinases, PKC and CK2 in
the presence of S100A4 as well (Kriajevska et al, 2002). The tumour
suppressor protein p53 has also been identified as a target for the
S100A4 protein. S100A4 binds to the extreme end of the C-terminal
regulatory domain of p53 in vitro and inhibits phosphorylation of
the p53 C-terminal peptide by PKC but not by CKII. Activation of
S100A4 expression in cell lines expressing wild-type p53 modulates
transcription of p53 target genes (p21/WAF, bax, thrombospondin-1
and mdm-2). Interaction of the S100A4 with p53 tumour suppressor
protein has been reported to induce the apoptosis promoting
function of p53 (Grigorian et al, 2001).
S100A4 has also been reported to interact in vitro with actin
filaments (Watanabe et al, 1993), with nonmuscle tropomyosin
(Takenaga et al, 1994b) and possibly interacts with tubulin
(Lakshmi et al, 1993). These data further suggest the possible
involvement of S100A4 in the regulation of cell motility and
cytoskeleton rearrangements. While interaction with the above-
mentioned proteins has been documented to be calcium-depen-
dent, there are reports of calcium-independent interactions of
S100A4. Chen et al (2001) using an optical biosensor, demon-
strated interaction of S100A4 with nonmuscle myosin and p53 in
calcium-independent manner suggesting appearance of novel
binding sites. Moreover, immunofluorescence studies revealed a
novel, calcium-independent localisation of S100A4 to the leading
edge of motile breast carcinoma cells (Kim and Helfman, 2003).
Further studies will be required to determine the biological
significance of the calcium-independent interactions and presum-
ably its effectors.
It was also shown that S100A4 can interact with another member
of S100 family. S100A4 can form heterodimers with S100A1 in vitro
(Tarabykina et al, 2000; Wang et al, 2000). Significantly it was
shown that the interaction between these two proteins, reduces
motility and metastatic ability of S100A4 transformed cells (Wang
et al, 2005).
EXTRACELLULAR S100A4
S100A4 can also be secreted and once extracellular can affect
several facets of tumour progression such as angiogenesis,
stimulation of cell motility, upregulation of matrix metallo-
proteinases (MMPs), modulation of tumour-related transcrip-
tion factors, and potentially as a stromal factor (Ambartsumian
et al, 2001; Belot et al, 2002; Schmidt-Hansen et al, 2004a, b).
S100A4 may be released from both tumour and/or stroma
cells by an as yet undetermined mechanism. S100A4 does not
have any of the known signal sequences to target it for secre-
tion through a classic vesicle transport pathway. Instead, it is
hypothesized that S100A4 is released from the cell through an
atypical pathway.
Proangiogenic capacity of S100A4 in vivo and its influence on
endothelial cells’ motility in vitro was the first indication of the
extracellular significance of S100A4 in tumour progression
(Ambartsumian et al, 2001). Angiogenic function of S100A4 was
associated with its ability to upregulate the expression of several
MMPs and downregulate their inhibitors (TIMPs) (Schmidt-
Hansen et al, 2004b). Inhibition of S100A4 in tumour cells results
in the downregulation of their invasive properties and reduces the
expression of MMPs and TIMPs (Bjornland et al, 1999).
Recombinant S100A4 stimulates motility and invasive growth of
3D capillary-like structures of mouse endothelial cells in Matrigel.
The growth of the capillary structures is not dependent on
stimulation of endothelial cells proliferation, but rather correlates
with the transcriptional modulation of genes involved in cell
motility and the proteolytic degradation of ECM. S100A4 activates
transcription of MMP-11, MMP-13, MMP-14, and uPA in
endothelial cells with the most pronounced increase in the
MMP-13 gene. There was a concomitant transcriptional down-
regulation of two out of three genes coding for protease inhibitors
– TIMP-l and TIMP-3, as well as PAT-I (Schmidt-Hansen et al,
2004b). More importantly, S100A4 induction of endothelial cells
was accompanied by increased levels of MMP activity as
demonstrated by casein zymography.
A significant impact of extracellular S100A4 protein was also
demonstrated with S100A4-negative VMR cells whose metastatic
capacity was strongly dependent on stromal interactions. Coin-
jection of these cells and S100A4 into the tail vein of mice followed
by several administrations of S100A4 into the blood stream
resulted in enhanced metastatic colonisation of the lung and liver.
These data suggest that S100A4 may mimic stromal signals to
activate tumour metastasis (Schmidt-Hansen et al, 2004a).
Furthermore, VMR tumour cells release factor(s) that triggers a
release of S100A4 from immortalised fibroblasts. In turn,
extracellular S100A4 protein induces the remodelling of tumour
cell cytoskeleton and adhesions contacts, stabilises the p53 protein
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and modulates expression of p53-regulated genes, as well as
activating MMPs (Schmidt-Hansen et al, 2004b).
Expression of S100A4 protein in different types of tumours may
suggest the ability of this protein to promote invasiveness and
metastasis of various human neoplasms. However the actual
mechanism of tumour-promoting function of S100A4 remains to
be determined. Recent studies of an S100A4-deficient mouse
model provided in vivo evidence that expression and release of
S100A4 from activated stroma cells in tumour are central both for
stimulation of tumour development and metastasis formation.
When highly metastatic mouse mammary carcinoma cell line
expressing high levels of S100A4 protein was introduced into
S100A4-deficient mice, a severe impairment both in tumour
incidence and uptake was observed. Moreover, no metastases were
detected in the lungs of the S100A4(/), that finally grew
tumours. This indicates that expression of S100A4 only in tumour
cells is not sufficient for stimulation of tumour growth and
metastasis, and implicates S100A4 expressing host-derived stroma
cells as the main source of metastasis-stimulating activity of
S100A4 (Grum-Schwensen et al, 2005).
Extracellular S100A4 was recently shown to influence cell
survival in neuronal cells as well as neurite outgrowth. Addition
of S100A4 resulted in protection of cells from the proapoptotic
stimuli as detected by inhibition of DNA fragmentation but not
caspases 3 and 6 activity (Pedersen et al, 2004). This cell protecting
function of S100A4 may be beneficial for metastatic cells for their
survival in blood stream and foreign microenvimnment of distal
organs. However, an opposing scenario of response to S100A4 was
recently reported by Pedersen et al (2004), who found that the
S100A4-secreting human osteosarcoma cell line OHS are more
sensitive to IFN-g-mediated apoptosis than anti-S100A4 ribozyme
transfected counterpart II-11b cells, which do not secrete S100A4
into conditioned medium. Addition of S100A4 to the cell medium
of II-11b cells induces apoptosis. This discrepancy in response to
extracellular S100A4 is suggestive of a strong dependence on cell
type. Notably, recombinant S100A4 protein added to cell culture
medium strongly stimulates differentiation of the rat hippocampal
neurons (Novitskaya et al, 2000).
It is not presently known whether the biological activity of
extracellular S100A4 is mediated via binding to a cell surface
receptor and the triggering of signal transduction in responsive
cells. However, the short exposure time (1–2 min) needed to
generate the response of neurons to S100A4 and the fact that
immobilised S100A4 protein can induce neuritogenesis indicates a
putative receptor-mediated signalling. Indeed, it was shown that
S100A4 treatment of hippocampal neurons induces activation
signalling pathways similar to pathways that can be mediated by
receptor tyrosine kinase, G protein-coupled receptors, or cytokine
receptors (Novitskaya et al, 2000).
The receptor for advanced glycation end products (RAGE) has
been identified as a putative receptor for several S100 proteins
(Hofmann et al, 1999; Huttunen et al, 2000). Soluble peptide of
RAGE blocks intracellular translocation of S100A4, S100A12,
S100A13, and S100B in endothelial cells. The S100 proteins
translocation was accompanied by activation of NF-kB, suggesting
interactions between RAGE and the S100 proteins (Hsieh et al,
2004). The interaction between S100A4 and RAGE nevertheless
remains inconclusive. Belot et al (2002) demonstrated that adding
S100A4 to the culture medium of two separate astrocytic tumour
cell lines strongly enhanced the migration rate of both cell lines
and activated changes in actin cytoskeleton. However, RAGE
mRNAs was found only in one of the cell line suggesting that the
S100A4 effect on astrocytic tumour cell motility was not solely
RAGE-mediated (Belot et al, 2002).
Taken together, we may speculate that S100A4 is an active
metastasis regulator that is secreted by tumour cells and tumour-
activated stromal cells. Extracellular S100A4 targets tumour or
endothelial cells by binding to an as yet unknown receptor and
triggering a signal transduction cascade and/or perhaps by
internalisation followed by interaction with the intracellular target
proteins. As a result, tumour cells acquire a more metastatic
phenotype with altered cell adhesion, motility, high proteolytic
activity, and increased survival potential.
FUTURE PERSPECTIVES
There are many questions that remain about the cellular function
of S100A4 and how it carries out its apparent influence on
metastatic progression. Although S100A4 is known to bind to a
number of cellular proteins, it remains to be determined how these
interactions affect the function of the binding partners, and
whether these interactions are relevant to the metastatic pheno-
type. Whether S100A4 alters oncogenic activation of specific
signalling pathways leading to changes in differential expression of
proteins needs to be explored. Discovering the function of a
protein highly correlated with metastasis and poor prognosis may
provide a leap forward in the treatment strategy of early cancer. By
identifying and characterising the interaction of S100A4 with its
effectors, we can supplement our understanding of how this
particular clinical marker mechanistically engages cells to adopt a
more motile, and thereby, more metastatic phenotype. Ultimately,
this greater understanding will ideally lead to the use of S100A4 as
not only a diagnostic and prognostic marker but also as a target for
therapeutic design.
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